Company Overview
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Recent Developments
- Dec 2025 Revenue of $54.23K (-97.9% YoY); net profit $-7.96M.
- Trailing 12 Months Year-on-year growth — revenue +1969.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -57.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -57.90% |
| 1 Year: | 1,969.70% |
Stock Price Performance
| 1 Year: | -90.68% |
| 6 Months: | -29.45% |
| 3 Months: | -71.15% |
| 1 Month: | -26.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -57.9% CAGR over 5 years.
- Trading 93.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HCWB HCW Biologics Inc. PHARMA | 2.51 | -0.15 | $4.61M | 0.00% | - | - | -57.90% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.07K | 6.55K | 15.61K | 27.01K | 6.54M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.05K | 5.24K | 12.48K | 21.61K | 11.07K |
| Gross Profit | - | - | - | 0 | 0 | 0 | 1.79M | 166.80K | 361.81K | 12.53K | 120.41K | 174.78K | 614.75K | 180.41K | 85.28K | - | 1.01K | 1.31K | 3.12K | 5.40K | 6.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.69M | 3.36M | 3.28M | 2.95M | 3.28M |
| Operating Income | - | -2.78M | -2.71M | -3.41M | -2.75M | -4.09M | -1.88M | -3.51M | -4.02M | -5.36M | -4.51M | -5.08M | -7.49M | -15.14M | -3.68M | - | -1.69M | -3.36M | -3.28M | -2.95M | 3.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.25M | -1.30M | -4.24M | 1.10M | 4.07M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 528.88K | 330.96K | 142.57K | 226.54K | 123.69K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.20M | -1.93M | -4.55M | 719.23K | 3.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 330.19K |
| Net Income | -2.38M | -2.78M | -2.71M | -2.84M | -2.75M | -4.09M | -2.06M | -3.51M | -3.91M | -5.07M | -4.30M | -4.94M | -7.47M | -15.28M | -3.90M | - | -2.20M | -1.93M | -4.55M | 719.23K | 3.47M |
| Diluted EPS | - | - | - | - | -0.66 | -0.14 | -0.06 | -0.10 | -0.11 | -0.14 | -0.12 | -0.14 | -0.20 | -16.16 | -4.13 | - | -11.82 | -5.39 | -12.12 | -6.12 | 2.22 |
| R&D Expense | - | 2.07M | 2.10M | 2.33M | 1.67M | 2.69M | 1.79M | 1.97M | 2.65M | 2.26M | 1.62M | 1.67M | 2.12M | 2.03M | 1.19M | - | 1.48M | 1.23M | 1.40M | - | 1.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.10M | 0 | 6.72M | 2.84M | 2.57M | 54.23K |
| Gross Profit | - | 0 | 2.59M | 560.36K | 959.40K | 10.85K |
| Operating Income | -5.82M | -13.37M | -15.08M | -25.72M | -29.46M | -13.16M |
| Net Income | -5.80M | -12.86M | -14.90M | -24.99M | -30.02M | -7.96M |
| Diluted EPS | - | -0.69 | -0.42 | -0.70 | -30.96 | -10.63 |
| R&D Expense | 7.26M | 8.17M | 9.34M | 7.68M | 6.39M | 5.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 15.40M | - | 46.81M | 28.51M | 30.24M | 24.52M |
| Current Assets | - | - | - | 34.07M | 6.40M | 5.70M | 2.28M |
| Cash & Equivalents | 7.36M | 8.46M | - | 22.33M | 3.60M | 4.67M | 1.95M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 417.69K | 1.54M | 582.20K | 32.17K |
| Total Liabilities | - | - | - | 9.38M | 15.05M | 37.01M | 21.76M |
| Current Liabilities | - | 1.00M | - | 2.96M | 8.75M | 29.63M | 21.06M |
| Long Term Debt | - | - | - | 6.41M | 6.30M | 7.38M | - |
| Total Debt | - | - | - | 6.41M | 6.30M | 13.69M | 6.81M |
| Total Equity | -9.68M | -16.72M | - | 37.43M | 13.46M | -6.77M | 2.76M |
| Shares Outstanding | - | - | - | 149.49K | 150.10K | 185.59K | 546.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.43M | -10.98M | -10.39M | -22.51M | -14.23M | -13.39M |
| Investing Cash Flow | -186.68K | -35.02M | 14.71M | 3.80M | -261.62K | 0 |
| Financing Cash Flow | 11.72M | 49.27M | 6.27M | -14.53K | 15.57M | 10.67M |
| Capital Expenditure | -186.68K | -47.26K | -10.28M | -6.20M | -261.62K | -0 |
| Free Cash Flow | -10.62M | -11.02M | -20.66M | -28.72M | -14.49M | -13.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 38.5% | 19.7% | 37.4% | 20.0% |
| Operating Margin % | -142.1% | - | -224.3% | -905.0% | -1,147.6% | -24,270.7% |
| Net Margin % | -141.5% | - | -221.7% | -879.5% | -1,169.7% | -14,677.1% |
| ROE % | 34.7% | - | -39.8% | -185.7% | 443.5% | -287.9% |
| ROCE % | -40.5% | - | -34.4% | -130.1% | -4,847.3% | -380.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 2.84% | 52.14K | $97.50K |
| 2 | Citadel Advisors Llc | 1.09% | 19.94K | $37.29K |
| 3 | HRT Financial LP | 0.74% | 13.58K | $25.40K |
| 4 | Vanguard Fiduciary Trust Co | 0.35% | 6.51K | $12.17K |
| 5 | Tower Research Capital LLC (TRC) | 0.22% | 4.12K | $7.70K |
| 6 | Connective Capital Management LLC | 0.18% | 3.34K | $6.24K |
| 7 | Vanguard Capital Management LLC | 0.11% | 2.00K | $3.75K |
| 8 | Golden State Wealth Management, Llc | 0.09% | 1.67K | $3.12K |
| 9 | Barclays Plc | 0.01% | 191 | $357 |
| 10 | Caitong International Asset Management Co., Ltd | - | 11 | $20 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCWB
$HCWB stock is down 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNOF9PUFBqazFoU0NiS2g4VkVWd2NFc3lpVXczdzF5ZV81Y2Rab0NHRDFXRTJkT012X1A2ZWFZTm1FcjhKX2RKZGJSVjBXWEUtXzlKYlRvYno2UlNfVFd6NW01WnFjYktDLVp1QXBpOExEdkpuYWpKSlZBeGlEb1BkNDJQcmVPWE5ONXRiME…
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9aOUo2aU5wdmRnN2RKdzRkWVVWN1g4Rkk5bkNqZlU1Z2pmRWRqV0FqcGxrc1VrWm4xQkJhOGFKTEVtY3Uxa2tDajBOaFVRN3RGcXVZVzF0QUFHT2JUOEhkUHNqX3pzaUM2d0FiUHBIdnVVeFhJYm1GSmpB?oc=5" target="_blank">HCW…
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOemFqU09JbkRTcTcxYXVzME92UVpfZ1l4NlZweVV0bDNPc2JNaTdrTFRjQXJrTWU5TXFlcEFodmZlRkhxeFlRSEZCNlBEem83cnd1dlF4ZWxhMDJiMERFM18tSndDaXJuaHhJUi1LNVpzVnJEdko3Q0Y1MmVaQ0VKVVpNeXY2MmpZZHQ0VG…
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5Zd1RsRWFHeHVPdU1VOGIxSkhYbWhLZ2o5SmtLbEN3eW95eHhJdm01LXhTRmFjN2JrUkJKeDJpOEJrVU1VdjF6ZXRtMXZsb0draVc2MklXemhWVGt6cmVxVFdoUUdIenhHdVF5VDhFeE1WZGhwSUNodWNRcC1tQQ?oc=5" target="_blan…
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1VZ216MjJKaFU4TmtiTUtPMzcxSW9KeU5kQmcwYzlHdFJCeGt2ckx2T3AtVFlIM0JtWnRqbFRBaWxRV3RiTkFnNg?oc=5" target="_blank">Hcw Biologics Stock Price Forecast. Should You Buy HCWB?</a> &nb…
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Distress - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPR0RoZk1fMDcyeXZHSGFxSkI2c1NEQUFPNE5Pc1VoVDdkMnp5MWZzdm55VFBRSEczbEZCZFJzT1NmT0NVSlRfalVGSkthRVJUZ1F5ZVNRTjFhOWhtVU1PdWFMZHh5Vm1YRFp0dVZKYXB1TWdlY0pkaDl3U0F0emZEYjBWZGgya1dNU2FOb3…
HCWB — Frequently Asked Questions
What is the current share price of HCW Biologics Inc. (HCWB)?
As of 2026-09-19 21:16 PDT, HCW Biologics Inc. (HCWB) trades at $2.51 on NasdaqCM. Its 52-week range is $1.61 to $36.12.
What is the market capitalisation of HCWB?
HCW Biologics Inc. (HCWB) has a market capitalisation of $4.61M on NasdaqCM.
What is the P/E ratio of HCWB?
HCWB trades at a trailing price-to-earnings (P/E) ratio of -0.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.41.
Is HCWB a good stock to buy?
This page provides a data-driven analysis of HCW Biologics Inc. (HCWB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.